| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 12/19/2001 | EP1162988A1 Wafer delivery system |
| 12/19/2001 | EP1162984A2 Use of cross linked polysaccharides for the inhibition of angiogenesis |
| 12/19/2001 | EP1162978A1 Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
| 12/19/2001 | EP1162970A2 Anti-inflammatory uses of manzamines |
| 12/19/2001 | EP0785781B1 Use of indole derivatives for the treatment of dermatological disorders peripheral neuropathied, arthritis, allergic or chronic obstructive airways disease, glaucoma and ocular inflammation |
| 12/19/2001 | EP0707849B1 Use of derivatives of 2,4-disubstituted phenols as 5-lipoxigenase inhibitors |
| 12/19/2001 | CN1327382A Improved formulation for topical non-invasive application in vivo |
| 12/19/2001 | CN1076352C 5-(2-imidazolinylamino) benzimidazole derivatives, their preparation and their use as alpha-2 adrenoceptor agaonists |
| 12/19/2001 | CN1076193C Chinese medicinal eyedrops |
| 12/18/2001 | US6331644 3-heteroatom substituted and two carbon homologs of 15-HETE and methods of use |
| 12/18/2001 | US6331637 N-Alkyl, N-Alkenyl, N-Alkynyl, N-Aryl and N-fused bicyclo or tricyclo thienyl-, furyl-,and Pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| 12/18/2001 | US6331566 Heteroatom-interrupted analogs of 15-hydroxyeicosatetraenoic acid and methods of use |
| 12/18/2001 | US6331556 Benzofuran-4-carboxylic acid amide derivatives used as phosphodiesterase iv or tumor necrosis factor inhibitors |
| 12/18/2001 | US6331410 Polynucleotides encoding a novel pyrR homolog |
| 12/18/2001 | US6331313 Controlled-release biocompatible ocular drug delivery implant devices and methods |
| 12/18/2001 | CA2202484C Use of indole derivatives for the treatment of various diseases |
| 12/18/2001 | CA2178161C Indole derivatives |
| 12/13/2001 | WO2001094612A2 Method for identifying medically valuable active substances |
| 12/13/2001 | WO2001094415A2 Nuclear hormone receptor |
| 12/13/2001 | WO2001094413A2 B7-related nucleic acids and polypeptides and their uses for immunomodulation |
| 12/13/2001 | WO2001094391A2 Intracellular signaling proteins |
| 12/13/2001 | WO2001094351A1 Caspase inhibitors and uses thereof |
| 12/13/2001 | WO2001094350A1 6-phenylpyrrolopyrimidinedione derivatives |
| 12/13/2001 | WO2001094347A1 Tetracyclic diketopiperazine compounds as pdev inhibitors |
| 12/13/2001 | WO2001094346A1 1,3,8-TRIAZA-SPIRO'4,5!DECAN-4-ONE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS |
| 12/13/2001 | WO2001094345A2 Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione |
| 12/13/2001 | WO2001094326A1 Novel thiazolidinedione derivatives and use thereof as drugs |
| 12/13/2001 | WO2001094321A1 Bicyclic cyclohexylamines and their use as nmda receptor antagonists |
| 12/13/2001 | WO2001094307A1 Propanolaminotetralines, preparation thereof and compositions containing same |
| 12/13/2001 | WO2001094293A2 Benzamide ligands for the thyroid receptor |
| 12/13/2001 | WO2001094279A2 Purification of xanthophylls from marigold extracts that contain high levels of chlorophylls |
| 12/13/2001 | WO2001093893A2 The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy |
| 12/13/2001 | WO2001093828A1 The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| 12/13/2001 | WO2001034550A3 15-hydroxyeicosatetraenoic acid analogs with enhanced metabolic stability and methods of their use in treating dry eye disorders |
| 12/13/2001 | WO2001034129A3 Heteroatom-interrupted analogs of 15-hydroxyeicosatetraenoic acid and methods of use |
| 12/13/2001 | US20010051648 Administering to a mammal for the treatment of dry eye or other disorders requiring the wetting of the eye a heteroatom such as nitrogen, oxygen or sulfur interrupted hydroxyeicosatetraenoic acid related compounds |
| 12/13/2001 | CA2412377A1 B7-related nucleic acids and polypeptides and their uses for immunomodulation |
| 12/13/2001 | CA2411536A1 The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| 12/13/2001 | CA2411062A1 Benzamide ligands for the thyroid receptor |
| 12/13/2001 | CA2411013A1 6-phenylpyrrolopyrimidinedione derivatives |
| 12/13/2001 | CA2411010A1 Tetracyclic diketopiperazine compounds as pdev inhibitors |
| 12/13/2001 | CA2409392A1 Intracellular signaling proteins |
| 12/13/2001 | CA2409015A1 Caspase inhibitors and uses thereof |
| 12/13/2001 | CA2408748A1 Nuclear hormone receptor |
| 12/13/2001 | CA2407164A1 Bicyclic cyclohexylamines and their use as nmda receptor antagonists |
| 12/13/2001 | CA2398277A1 The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for protecting cns cells from glutamate toxicity |
| 12/12/2001 | EP1161942A2 Ophthalmic composition |
| 12/12/2001 | EP1161448A1 49 human secreted proteins |
| 12/12/2001 | EP1161447A1 50 human secreted proteins |
| 12/12/2001 | EP1161433A1 Tyrosine kinase inhibitors |
| 12/12/2001 | EP1161429A2 Heterocyclic compounds as adenosine deaminase inhibitors |
| 12/12/2001 | EP1161419A1 Spirocyclic ketones and their use as tachykinin antagonists |
| 12/12/2001 | EP1161415A2 N-cyanomethylamides as protease inhibitors |
| 12/12/2001 | EP1161410A1 Retinoid antagonists and use thereof |
| 12/12/2001 | EP1161258A1 Compositions and methods of use of ldl-like receptor ligands for the treatment of cancer and angiogenic-based disease |
| 12/12/2001 | EP1161245A1 Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula |
| 12/12/2001 | EP1161240A1 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| 12/12/2001 | EP1161235A1 Combinations for the treatment of diseases involving angiogenesis |
| 12/12/2001 | EP0938471B1 The preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| 12/12/2001 | EP0889730B1 Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation |
| 12/12/2001 | CN1326509A MOraxella catarrhalis ABSB034 polypeptides and uses thereof |
| 12/12/2001 | CN1326457A 4-aminopyrrolopyrimidines as kinase inhibitors |
| 12/12/2001 | CN1326456A 8-Azabicyclo [3.,2.1] Oct-2-Ene and-Octane derivatives |
| 12/12/2001 | CN1326441A 4-Aroyl-Piperidin-CCR-3 receptor antagonists III |
| 12/12/2001 | CN1326362A Model and method for angiogenesis inhibition |
| 12/12/2001 | CN1326344A PUFA supplements |
| 12/11/2001 | US6329557 Dispersing saponified extract in water to form dispersion; mixing to form aqueous phase; separating from residue, contacting with nonpolar solvent to dissolve lipid-soluble compounds; separating precipitate; washing |
| 12/11/2001 | US6329418 Substituted pyrrolidine hydroxamate metalloprotease inhibitors |
| 12/11/2001 | US6329397 Hydroxy pipecolate hydroxamic acid derivatives |
| 12/06/2001 | WO2001092304A2 Transporters and ion channels |
| 12/06/2001 | WO2001092274A2 Naaladase inhibitors for treating retinal disorders and glaucoma |
| 12/06/2001 | WO2001092273A2 Benzenedicarboxylic acid derivatives |
| 12/06/2001 | WO2001092267A2 Dihydropyridine compounds for the inhibition of calcium-influx |
| 12/06/2001 | WO2001092253A2 Inhibitors of alpha l beta 2 mediated cell adhesion |
| 12/06/2001 | WO2001092239A1 Biciclic cyclohexylamines and their use as nmda receptor antogonists |
| 12/06/2001 | WO2001092227A1 Chemical compounds |
| 12/06/2001 | WO2001092220A1 Aminothiolester compounds, pharmaceutical and cosmetic compositions containing same and uses thereof |
| 12/06/2001 | WO2001092210A1 Compounds for modulating the rage receptor |
| 12/06/2001 | WO2001092204A1 Cyclohexylamine derivatives as subtype selective nmda receptor antagonists |
| 12/06/2001 | WO2001091799A2 Medicament for the treatment of immune reactions in the eye |
| 12/06/2001 | WO2001091795A1 Ectocornea extension promoters |
| 12/06/2001 | WO2001091782A1 Pralmorelin-containing nasal drop preparations |
| 12/06/2001 | WO2001091779A1 Remedies for corneal injuries |
| 12/06/2001 | WO2001091772A2 Compositions for treating eye discomfort containing herbals and/or nutritional supplements and/or minerals and/or vitamins |
| 12/06/2001 | WO2001091770A2 Compositions for treating eye discomfort containing herbals and/or nutritional supplements and/or minerals and/or vitamins |
| 12/06/2001 | WO2001091765A2 Compositions for treating eye discomfort containing herbals and/or nutritional supplements and/or minerals and/or vitamins |
| 12/06/2001 | WO2001091756A2 S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders |
| 12/06/2001 | WO2001091729A1 Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base |
| 12/06/2001 | WO2001091682A1 Composition and applicator for topical substance delivery |
| 12/06/2001 | WO2001049673A3 Compounds and methods for modulation of estrogen receptors |
| 12/06/2001 | WO2001046392A3 Homologues of human heparanase and splice variants thereof |
| 12/06/2001 | WO2001019800A3 Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| 12/06/2001 | WO2001012775A8 25 human secreted proteins |
| 12/06/2001 | WO2001001972A3 SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE |
| 12/06/2001 | WO2000077018A3 Purine derivatives |
| 12/06/2001 | US20010049371 Reducing levels of tumor necrosis factor alpha; inhibition of undesireable levels of matrix metalloproteinases |
| 12/06/2001 | US20010049106 ADAM (A Disintegrin And Metalloprotease) family of metalloproteases, and in addition contain thrombospondin domain (TS); treating diabetes, arthritis, cancer, solid tumors, autoimmune diseases |
| 12/06/2001 | DE10026699A1 Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage Formulation of heparin, glycosaminoglycan or Heparinoidbasis and use of the formulation and the formulation base |
| 12/06/2001 | DE10025920A1 Verfahren und Mittel zur Behandlung von Immunreaktionen am Auge Method and agent for the treatment of immune responses in the eye |
| 12/06/2001 | CA2599562A1 Compounds for modulating the rage receptor |